Your Cheddar hosts Kristen Scholer and Tim Stenovec break down today's top stories, from taxes to crypto.
Shares of Kodak more than doubled Tuesday after the company announced plans to jump into the cryptocurrency market. The photo imaging giant has plans for an initial coin offering called KodakCoin. The digital currency would be the backbone of a platform to help photographers license their work and track unauthorized use of their photos.
Plus, the newly passed tax law could save Americans billions of dollars on their utility bills. Electric companies in Massachusetts, Illinois, Oregon, and other states have announced plans to pass tax savings onto their customers.
YouTube will offer creators a way to rejoin the streaming platform if they were banned for violating COVID-19 and election misinformation policies that are no longer in effect.
Lukas Alpert of MarketWatch explores how networks, brands, and ad buyers absorb the shockwaves when late‑night show hosts are suddenly cut — and brought back.
A new poll finds U.S. adults are more likely than they were a year ago to think immigrants in the country legally benefit the economy. That comes as President Donald Trump's administration imposes new restrictions targeting legal pathways into the country. The Associated Press-NORC Center for Public Affairs Research survey finds Americans are more likely than they were in March 2024 to say it’s a “major benefit” that people who come to the U.S. legally contribute to the economy and help American companies get the expertise of skilled workers. At the same time, perceptions of illegal immigration haven’t shifted meaningfully. Americans still see fewer benefits from people who come to the U.S. illegally.
Shares of Tylenol maker Kenvue are bouncing back sharply before the opening bell a day after President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines and autism. Trump told pregnant women not to use the painkiller around a dozen times during the White House news conference Monday. The drugmaker tumbled 7.5%. Shares have regained most of those losses early Tuesday in premarket trading.
